Researchers Report Clinical Proof-of-Concept Data for Vivace

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Florida , Orlando , China , Texas , American , Tracy Tang , Tim Brons , Timothya Yap , University Of Texas Md Anderson Cancer Center , American Association For Cancer Research , Vivace Therapeutics Inc , Prnewswire Vivace Therapeutics Inc , Well Tolerated , Demonstrates Antitumor Activity , Advanced Mesothelioma , First Therapeutic Targeting , Hippo Pathway , Demonstrate Clinical Activity , American Association , Cancer Research , Annual Meeting , Cancer Center , Vivace Therapeutics , Molecular Cancer Therapeutics Award , Outstanding Journal Article , Molecular Cancer Therapeutics , Molecule Inhibitors , Selectively Inhibit Proliferation , Tumor Growth , Francisco Bay Area , Canaan Partners , Xihealthcare Ventures , Cenova Capital , Sequoia Capital China , Boxer Capital , Strategic Partners ,